[Screening and management of cardiovascular risk factors in systemic lupus erythematosus: Recommendations for clinical practice based on the literature and expert opinion].

[1]  L. Arnaud,et al.  [Assessing the cardiovascular risk in patients with systemic lupus erythematosus]. , 2014, La Revue de medecine interne.

[2]  M. Lapeyre-Mestre,et al.  Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database , 2012, Lupus.

[3]  L. Magder,et al.  Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. , 2011, Rheumatology.

[4]  M. Taskinen,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[5]  M. O’Donnell,et al.  Effect of aspirin on mortality in the primary prevention of cardiovascular disease. , 2011, The American journal of medicine.

[6]  S. Yusuf,et al.  Changes in albuminuria predict mortality and morbidity in patients with vascular disease. , 2011, Journal of the American Society of Nephrology : JASN.

[7]  C. Mok,et al.  Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double‐blind, placebo‐controlled trial , 2011, Arthritis care & research.

[8]  M. Khamashta,et al.  Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies , 2011, Lupus.

[9]  L. Magder,et al.  Lupus Atherosclerosis Prevention Study (LAPS) , 2010, Annals of the rheumatic diseases.

[10]  Stampfer,et al.  Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. , 2009, Arthritis and rheumatism.

[11]  J. Nossent,et al.  Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus , 2009, Lupus.

[12]  I. Holme,et al.  Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study. , 2009, Arthritis and rheumatism.

[13]  M. Petri,et al.  Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. , 2007, Arthritis and rheumatism.

[14]  R. Schmieder,et al.  Renin-angiotensin system and cardiovascular risk , 2007, The Lancet.

[15]  D. Gladman,et al.  Mortality in systemic lupus erythematosus. , 2006, The Journal of rheumatology. Supplement.

[16]  M. Dougados,et al.  Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. , 2006, Joint, bone, spine : revue du rhumatisme.

[17]  D. Gladman,et al.  Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study , 2005, Annals of the rheumatic diseases.

[18]  F. Granath,et al.  Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. , 2004, The Journal of rheumatology.

[19]  R. Schlienger,et al.  Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. , 2004, The American journal of cardiology.

[20]  M. Abrahamowicz,et al.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. , 2001, Arthritis and rheumatism.

[21]  F. Sarasin,et al.  Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. , 2000, Archives of internal medicine.

[22]  R. Ross.  Atherosclerosis is an inflammatory disease , 1999 .

[23]  M. Urowitz,et al.  The bimodal mortality pattern of systemic lupus erythematosus. , 1976, The American journal of medicine.

[24]  E. Yow,et al.  Use of atorvastatin in systemic lupus erythematosus in children and adolescents. , 2012, Arthritis and rheumatism.

[25]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[26]  D. Gladman,et al.  Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. , 2007, The Journal of rheumatology.

[27]  D. Gladman,et al.  Premature atherosclerosis in systemic lupus erythematosus. , 2005, Rheumatic diseases clinics of North America.